Exploratory Evaluation of EGFR-Targeted Anti-Tumor Drugs for Lung Cancer Based on Lung-on-a-Chip

被引:19
|
作者
Tan, Jianfeng [1 ,2 ]
Sun, Xindi [3 ]
Zhang, Jianhua [1 ]
Li, Huili [4 ]
Kuang, Jun [1 ]
Xu, Lulu
Gao, Xinghua [3 ]
Zhou, Chengbin [2 ,4 ]
机构
[1] Southern Med Univ, Dept Thorac Surg, Shenzhen Hosp, Shenzhen 518101, Peoples R China
[2] Southern Med Univ, Sch Clin Med 2, Guangzhou 510030, Peoples R China
[3] Shanghai Univ, Mat Genome Inst, Shanghai 200444, Peoples R China
[4] Guangdong Acad Med Sci, Dept Cardiovasc Surg, Guangdong Prov Cardiovasc Inst, Guangdong Prov Peoples Hosp, Guangzhou 510030, Peoples R China
来源
BIOSENSORS-BASEL | 2022年 / 12卷 / 08期
关键词
lung-on-a-chip; drug evaluation; EGFR; lung cancer; targeted therapy; GEFITINIB; MODELS;
D O I
10.3390/bios12080618
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
In this study, we used three-dimensional (3D) printing to prepare a template of a microfluidic chip from which a polydimethylsiloxane (PDMS)lung chip was successfully constructed. The upper and lower channels of the chip are separated by a microporous membrane. The upper channel is seeded with lung cancer cells, and the lower channel is seeded with vascular endothelial cells and continuously perfused with cell culture medium. This lung chip can simulate the microenvironment of lung tissue and realize the coculture of two kinds of cells at different levels. We used a two-dimensional (2D) well plate and a 3D lung chip to evaluate the effects of different EGFR-targeting drugs (gefitinib, afatinib, and osimertinib) on tumor cells. The 3D lung chip was superior to the 2D well plate at evaluating the effect of drugs on the NCI-H650, and the results were more consistent with existing clinical data. For primary tumor cells, 3D lung chips have more advantages because they simulate conditions that are more similar to the physiological cell microenvironment. The evaluation of EGFR-targeted drugs on lung chips is of great significance for personalized diagnosis and treatment and pharmacodynamic evaluation.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Metabolic approach to EGFR-targeted therapy in non-small cell lung cancer
    Kam, Yoonseok
    Swain, Pamela
    Romero, Natalia
    Dranka, Brian P.
    CANCER RESEARCH, 2019, 79 (13)
  • [22] Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
    Favorito, Valentina
    Ricciotti, Ilaria
    De Giglio, Andrea
    Fabbri, Laura
    Seminerio, Renata
    Di Federico, Alessandro
    Gariazzo, Eleonora
    Costabile, Silvia
    Metro, Giulio
    EXPERT OPINION ON EMERGING DRUGS, 2024, 29 (02) : 139 - 154
  • [23] Nanofiber membrane supported lung-on-a-chip microdevice for anti-cancer drug testing
    Yang, Xingyuan
    Li, Kaiyan
    Zhang, Xu
    Liu, Chang
    Guo, Bingkun
    Wen, Weijia
    Gao, Xinghua
    LAB ON A CHIP, 2018, 18 (03) : 486 - 495
  • [24] Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer
    Jeannot, Victor
    Gauche, Cony
    Mazzaferro, Silvia
    Couvet, Morgane
    Vanwonterghem, Laetitia
    Henry, Maxime
    Didier, Chloe
    Vollaire, Julien
    Josserand, Veronique
    Coll, Jean-Luc
    Schatz, Christophe
    Lecommandoux, Sebastien
    Hurbin, Amandine
    JOURNAL OF CONTROLLED RELEASE, 2018, 275 : 117 - 128
  • [25] IL-17A induces EGFR-targeted therapy resistance via enhancing EGFR activation in lung cancer
    Lee, Kai Ling
    Chung, Chi-Li
    Chien, Ming-Hsien
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [26] EGFR-TARGETED SELECTIVE GENE THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
    Yamaguchi, Miki
    Nakamura, Kiminori
    Sakuragi, Naoya
    Kato, Kazunori
    Hamada, Hirofumi
    JOURNAL OF GENE MEDICINE, 2010, 12 (12): : 1056 - 1057
  • [27] Therapeutic Efficacy and Safety Profile of EGFR-Targeted Oncolytic Ad Nanocomplex in Orthotopic Lung Tumor Model
    Yoon, A-Rum
    Kasala, Dayananda
    Li, Yan
    Hong, Jinwoo
    Lee, Wonsig
    Jung, Soo-Jung
    Yun, Chae-Ok
    MOLECULAR THERAPY, 2016, 24 : S46 - S46
  • [28] Circulating Tumor DNA for Noninvasive Monitoring of Non-Small Cell Lung Cancer Patients Receiving EGFR-Targeted Therapies
    Tsui, Dana
    Muhammed, Murtaza
    Wong, Alvin S. C.
    Rueda, Oscar M.
    Forshew, Tim
    Soo, Ross
    Wong, H. I.
    Goh, Boon Cher
    Eisen, Tim
    Marass, Francesco
    Gale, Davina
    Liu, Wei
    Chin, Tan Min
    Rosenfeld, Nitzan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S358 - S359
  • [29] KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies
    Maus, M. K. H.
    Grimminger, P. P.
    Mack, P. C.
    Astrow, S. H.
    Stephens, C.
    Zeger, G.
    Hsiang, J.
    Brabender, J.
    Friedrich, M.
    Alakus, H.
    Hoelscher, A. H.
    Lara, P.
    Danenberg, K. D.
    Lenz, H. J.
    Gandara, D. R.
    LUNG CANCER, 2014, 83 (02) : 163 - 167
  • [30] Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer
    Ye, Mingtong
    Wang, Sufan
    Wan, Ting
    Jiang, Rui
    Qiu, Yun
    Pei, Lei
    Pang, Nengzhi
    Huang, Yuanling
    Huang, Yufeng
    Zhang, Zhenfeng
    Yang, Lili
    JOURNAL OF CANCER, 2017, 8 (18): : 3774 - 3784